About US
Contact us
-
Genmab signs ofatumumab transfer agreement with GSK and NovartisDenmark-based Genmab has signed an agreement with British drug-maker GlaxoSmithKline (GSK) and Swiss pharmaceutical company Novartis for the conditional transfer of ofatumumab collaboration contract f2014/11/4
-
CFDA, General Administration of Customs and General Administration of Sport jointly issue Administrative Measures for Import and Export of Anabolic Agents and Peptide HormonesIn accordance with the relevant requirements of the State Council on deepening the reform of administrative approval system, the approval of the import of anabolic agents and peptide hormones is autho2014/11/4
-
British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes.British drug-maker GlaxoSmithKline (GSK) has introduced a new once-daily bronchodilator treatment, Incruse Ellipta (umeclidinium) in the UK. A long-acting muscarinic antagonist (LAMA), Incruse has be2014/11/3
-
AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA approvalBritish-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes. Xigduo XR is a combin2014/11/3
-
Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal B diseaseUS-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young adults. As part of th2014/11/3
-
Qiagen and Astellas Pharma to develop companion diagnostics for cancer and other diseasesQiagen has signed a master collaboration agreement with global pharmaceutical company Astellas Pharma to develop and commercialise companion diagnostics, combined with the latter's drugs for use in ca2014/10/31
-
GSK launches bronchodilator treatment Incruse Ellipta in UKBritish drug-maker GlaxoSmithKline (GSK) has introduced a new once-daily bronchodilator treatment, Incruse Ellipta (umeclidinium) in the UK. A long-acting muscarinic antagonist (LAMA), Incruse has be2014/10/31
-
Johnson & Johnson unveils Asia Pacific Innovation Center in Shanghai, ChinaJohnson & Johnson Innovation has launched the Asia Pacific Innovation Center in Shanghai, China, with satellites in Singapore, Australia and Japan. The new centre will boost Johnson & Johnson2014/10/31
-
Merck’s Keytruda receives FDA breakthrough therapy designation to treat NSCLCMerck has received breakthrough therapy designation from US Food and Drug Administration (FDA) for its Keytruda (pembrolizumab) to treat patients with epidermal growth factor receptor (EGFR) mutation-2014/10/30
-
EU IMI launches new consortium to develop economic models for pharmaceutical industryA new European consortium Driving Reinvestment in research and development and Responsible Antibiotic Use (Drive AB) has been launched, to deal with the growing global threat of antibiotic resistance.2014/10/30